Morgan Stanley Initiates Coverage On Immix Biopharma with Overweight Rating, Announces Price Target of $20

Morgan Stanley analyst Judah Frommer initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Overweight rating and announces Price Target of $20.